JP2023524981A5 - - Google Patents

Info

Publication number
JP2023524981A5
JP2023524981A5 JP2022567283A JP2022567283A JP2023524981A5 JP 2023524981 A5 JP2023524981 A5 JP 2023524981A5 JP 2022567283 A JP2022567283 A JP 2022567283A JP 2022567283 A JP2022567283 A JP 2022567283A JP 2023524981 A5 JP2023524981 A5 JP 2023524981A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
peptide
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022567283A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524981A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/031260 external-priority patent/WO2021226439A2/en
Publication of JP2023524981A publication Critical patent/JP2023524981A/ja
Publication of JP2023524981A5 publication Critical patent/JP2023524981A5/ja
Pending legal-status Critical Current

Links

JP2022567283A 2020-05-08 2021-05-07 操作されたリラキシンおよびその使用の方法 Pending JP2023524981A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063021814P 2020-05-08 2020-05-08
US63/021,814 2020-05-08
PCT/US2021/031260 WO2021226439A2 (en) 2020-05-08 2021-05-07 Engineered relaxins and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026081891A Division JP2026130024A (ja) 2020-05-08 2026-05-14 操作されたリラキシンおよびその使用の方法

Publications (2)

Publication Number Publication Date
JP2023524981A JP2023524981A (ja) 2023-06-14
JP2023524981A5 true JP2023524981A5 (cg-RX-API-DMAC7.html) 2025-11-18

Family

ID=78468429

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022567283A Pending JP2023524981A (ja) 2020-05-08 2021-05-07 操作されたリラキシンおよびその使用の方法

Country Status (10)

Country Link
US (1) US20230174610A1 (cg-RX-API-DMAC7.html)
EP (1) EP4146681A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023524981A (cg-RX-API-DMAC7.html)
KR (1) KR20230008791A (cg-RX-API-DMAC7.html)
CN (1) CN115768801A (cg-RX-API-DMAC7.html)
AU (1) AU2021268355A1 (cg-RX-API-DMAC7.html)
CA (1) CA3180662A1 (cg-RX-API-DMAC7.html)
IL (1) IL297951A (cg-RX-API-DMAC7.html)
MX (1) MX2022013770A (cg-RX-API-DMAC7.html)
WO (1) WO2021226439A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023086913A2 (en) 2021-11-11 2023-05-19 Tectonic Therapeutic, Inc. Relaxin-2 fusion protein analogs and methods of using same
JP2024546877A (ja) * 2021-12-15 2024-12-26 メドイミューン・リミテッド ヘテロ二量体リラキシン融合物を使用した治療
EP4713001A2 (en) * 2023-05-18 2026-03-25 Tectonic Operating Company, Inc. Relaxin-2 fusion protein analogs and methods of using same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4835251A (en) * 1986-06-23 1989-05-30 Genetech, Inc. Method of chain combination
US20110245469A1 (en) * 2010-04-02 2011-10-06 Athena Discovery, Inc. Intermediates formed in biosynthesis of relaxin-fusion proteins with extended in vivo half-lives
US9567386B2 (en) * 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
AU2012280474A1 (en) * 2011-07-01 2014-01-16 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
WO2015038938A1 (en) * 2013-09-13 2015-03-19 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
CN115837014A (zh) * 2016-05-18 2023-03-24 摩登纳特斯有限公司 编码松弛素的多核苷酸
WO2018138170A1 (en) * 2017-01-25 2018-08-02 Medimmune, Llc Relaxin fusion polypeptides and uses thereof
SG10201912034UA (en) * 2017-02-08 2020-02-27 Bristol Myers Squibb Co Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof

Similar Documents

Publication Publication Date Title
JP6265564B2 (ja) 延長組換えポリペプチドおよび延長組換えポリペプチドを含む組成物
US11845782B2 (en) Relaxin fusion polypeptides and uses thereof
CA2667280C (en) Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
JP2023518596A5 (cg-RX-API-DMAC7.html)
CN102481331A (zh) 葡萄糖调节多肽及其制备和使用方法
CA2691898A1 (en) Bifunctional fusion proteins of the alpha-melanocyte stimulating hormone (alpha-msh) and atrial natriuretic protein (anp) and uses in hypertension and acute kidney injury
JP2024532503A5 (cg-RX-API-DMAC7.html)
CN102153652A (zh) 一种融合蛋白的表达方法及用途
CN101240033B (zh) 一种促胰岛素分泌肽与人血清白蛋白的融合蛋白及其制备方法
CA2616551A1 (en) Chimeric therapeutic agents
JP2024543455A5 (cg-RX-API-DMAC7.html)
WO2026082147A1 (zh) 一种双靶点受体激动剂融合蛋白及其应用
WO1999063086A2 (en) Insulin-like growth factor binding protein-3 variants
WO2023280133A1 (zh) 融合蛋白及其应用
CN111234015A (zh) 用于延长药物半衰期的抗体、其融合蛋白和应用
CN105085659B (zh) 一种重组利钠肽及其制备方法
CN118344462A (zh) 一种用于肺部给药的索马鲁肽突变体、融合蛋白及相关产品
CN103601808B (zh) 钠肽、制备方法及其在制备基因工程药物中的应用
RU2021136703A (ru) Новый модифицированный слитый белок fc-фрагмента иммуноглобулина и его применение
CN104447982B (zh) 一种人松弛素h2前体及其制备方法和应用
RU2025118082A (ru) Рекомбинантный гемоглобин
WO2026082073A1 (zh) 一种嵌合利钠肽或其变体及其应用
CN116063562A (zh) 一种长效人重组胰高血糖素样肽-1及其应用
WO2026055636A1 (en) Peptides and compositions for improving glucose levels
Veis et al. Type I procollagen heterotrimer assembly is linked to subtle differences in the structures of the pro-α 1 (I) and pro-α 2 (I)-carboxyl-propeptides